71.09
0.00 (0.0%)
0.00 (0.0%)
Upgrade to Real-Time
Premarket
| Volume | 4 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | BMY | NYSE | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 71.09 | 04:34:51 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 71.09 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 2 | 4 | - | 53.22 - 80.59 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:34:51 | 1 | $ 70.74 | USD |
Period:
Draw Mode:
Bristol Myers Squibb Co Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 151.80B | 2.14B | 2.13B | $ 46.39B | $ 6.56B | 3.12 | 23.60 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ 2.01 | 3.04% | 10/06/22 | -95.73k | 0.30% |
Bristol Myers Squibb News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BMY Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 70.14 | 72.61 | 69.69 | 71.08 | 11,129,073 | 0.95 | 1.35% |
| 1 Month | 68.94 | 75.99 | 68.12 | 70.78 | 11,026,824 | 2.15 | 3.12% |
| 3 Months | 75.50 | 75.99 | 65.95 | 72.01 | 9,623,261 | -4.41 | -5.84% |
| 6 Months | 74.00 | 80.59 | 65.95 | 74.56 | 12,167,665 | -2.91 | -3.93% |
| 1 Year | 59.39 | 80.59 | 53.22 | 68.45 | 13,045,219 | 11.70 | 19.7% |
| 3 Years | 48.84 | 80.59 | 45.76 | 63.43 | 12,817,426 | 22.25 | 45.56% |
| 5 Years | 64.41 | 80.59 | 41.19 | 59.58 | 11,676,839 | 6.68 | 10.37% |
Bristol Myers Squibb Description
| Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power. |